Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02785250 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 27, 2016
Last Update Posted : June 18, 2021
|
Sponsor:
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | October 2020 |
| Estimated Study Completion Date : | May 2025 |